Health Condition 1: K929- Disease of digestive system, unspecified
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Control Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: All patients with histology-proven Pancreatic ductal adenocarcinoma who underwent Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy and underwent curative pancreatic resections The period for recruitment -1st January 2015 to 31st December 2023
Exclusion criteria
Exclusion criteria: Final histology nonpancreatic ductal adenocarcinoma Patients who were deemed inoperable during surgical exploration Tumors epicenter in periampullary region (ampulla of vater, duodenum, distal bile duct) Treatment date outside of study protocol Lost to follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the factors determining tumor response after NAT in patients of PDAC treated with curative intent. Timepoint: At the end of study | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the impact of surgical outcome on OS & DFS Timepoint: 5 years after the surgery;To study the impact of pCR on OS & DFSTimepoint: 5 years after the surgery | — |
Countries
India, United States of America
Contacts
Public ContactDr Shailesh Shrikhande
TATA MEMORIAL HOSPITAL
Outcome results
None listed